Pancragen and the Khavinson bioregulator family, anyone actually tracking metabolic markers?

Posted by sleep_coastal in Research & News - 7 points, 4 comments.

I have been looking into Pancragen lately, one of the Khavinson short peptide bioregulators, and the claims around it are pretty ambitious for what it is. It is just a four amino acid peptide, Lys-Glu-Asp-Trp, and the proposed mechanism is that it regulates gene expression in pancreatic tissue, supposedly supporting both endocrine and exocrine function along with carbohydrate metabolism. That is a big claim for four amino acids.

Anecdotally I have messed around with a couple of the Khavinson peptides before, Cortagen and Epitalon mostly, and the effects were subtle but real enough that I did not write them off entirely. But pancreatic tissue regeneration is a whole different animal and I think it warrants more skepticism than the anti-aging crowd tends to apply. The Russian literature on these bioregulators goes back decades but the Western data is thin and I keep wondering how much of it would hold up under independent replication.

What I do find interesting is the course-based protocol idea, short repeated cycles rather than chronic daily use, because that at least makes some biological sense if you think of it as a signal pulse rather than a daily supplement you just stay on forever. My actual question is whether anyone here has run Pancragen with fasting glucose or HbA1c tracked before and after. I am not talking about vibes or subjective energy reports, I mean actual numbers from a glucometer or labwork. Because if the metabolic angle is real even partially, that would be worth a much closer look, but I am skeptical enough that I would want to see real markers before I took any of the claims seriously.

Comments

• fasted_scientist: The Russian literature on these bioregulators is one of those things that sounds impressive until you actually try to read it. A lot of it is in obscure journals, small sample sizes, and the methodology sections leave a lot to be desired. I tried looking into Epitalon a while back and found the same issue, loads of papers but very few that would pass muster in a decent peer-reviewed setting. The course-based protocol thing you mentioned is interesting though. If these short peptides actually wo
• midwest_scientist: Honestly you are spot on about the Russian literature. I looked into Epitalon papers a while back and the methodology is just painful to read. Small groups, no blinding, sometimes not even a proper control group. It is hard to separate real signal from noise in that kind of work. The pulsing idea does make sense to me though. I ran Epitalon in a short course, maybe 10 days, and the sleep effects I noticed were within that window. Could be coincidence, but pulsing at least avoids the question of
• sleep_coastal: The lack of blinding in those papers is EXACTLY why I am skeptical. It makes the data feel more like anecdotal reports than actual science. I agree on the pulsing though. For me, the sleep shift with Epitalon was the only thing that felt obvious, so keeping the cycles short just seems smarter. Do you think the downregulation risk is higher with the organ specific ones like Pancragen compared to the more general ones?
• sleep_coastal: You hit the nail on the head about those journals. I spent way too long digging through some translated Russian papers and the math was just messy. It is hard to trust the signal when the noise is that loud. Anecdotally, the pulsing idea makes sense for gene signaling, but I am still skeptical. Do you think the small sample sizes might actually be masking some of the metabolic shifts, or is it just bad science?

Community discussion - research and educational context only. Not medical advice.